Status: Finalised First registered on: 27/06/2013
Last updated on: 22/12/2021
1. Study identification
EU PAS Register NumberEUPAS4207
Official titleOutpatient care with long-acting bronchodilators:
Study title acronymDACCORD
Study typeObservational study
Brief description of the studyThe DACCORD registry aims to close the apparent gap between populations in clinical trials and daily live by evaluating different treatment approaches in COPD with respect to their efficacy and tolerability and their impact on patient-related outcomes. DACCORD is a prospective observational German registry since November 2012, evaluating data of 16,000 COPD patients from approximately 700 sites distributed in three different cohorts. To guarantee the best selection under the conditions of a non-interventional study, patients have to fulfill the criteria for recruitment to the German COPD DMP (Disease Management Program), implemented by the statutory health insurances. The primary objective is to evaluate diagnosis and therapy of outpatient-treated COPD patients under special consideration of individual treatment success, determined by therapy adherence, symptoms and patient-reported outcomes. Among the secondary objectives are the characteristics of exacerbations and COPD progression, measured by lung function and CAT (COPD Assessment Test) questionnaire
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)? Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicableCNVA237ADE01
2. Research centres and Investigator details
Coordinating study entity
Centre nameNovartis Pharmaceuticals
Centre locationBasel, Switzerland
Details of (Primary) lead investigator
Title Ms
Last name Clinical Disclosure Officer
First name Novartis
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Multiple centres

In total how many centres are involved in this Study?700
Countries in which this study is being conducted
National study

Germany
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed20/06/2012
Start date of data collection05/11/2012
Start date of data analysis01/06/201514/03/2021
Date of interim report, if expected01/11/201525/01/2019
Date of final study report01/02/202227/10/2021
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesNovartis Pharmaceuticals100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Ms
Last name Clinical Disclosure Officer
First name Novartis
Address line 1Novartis Pharmaceuticals
Address line 2CH-4002 
Address line 3 
CityBasel 
Postcode 
CountrySwitzerland
Phone number (incl. country code)416132-41111 
Alternative phone number 
Fax number (incl. country code) 
Email address Trialandresults.registries@novartis.com
Public Enquiries
Title Ms 
Last name Clinical Disclosure Officer 
First name Novartis 
Address line 1Novartis Pharmaceuticals 
Address line 2CH-4002 
Address line 3 
CityBasel 
Postcode 
CountrySwitzerland 
Phone number (incl. country code)41613241111 
Alternative phone number 
Fax number (incl. country code)41713248001 
Email address Trialandresults.registries@novartis.com 
Top